71 related articles for article (PubMed ID: 3941752)
1. Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice.
Diani AR; Peterson T; Sawada G; Jodelis K; Wyse BM; Gilchrist BJ; Hearron AE; Chang AY
Nephron; 1986; 42(1):72-7. PubMed ID: 3941752
[TBL] [Abstract][Full Text] [Related]
2. Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats.
Chang AY; Wyse BM; Gilchrist BJ; Peterson T; Diani AR
Diabetes; 1983 Sep; 32(9):830-8. PubMed ID: 6354790
[TBL] [Abstract][Full Text] [Related]
3. Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice.
Diani AR; Peterson T; Sawada GA; Wyse BM; Gilchrist BJ; Hearron AE; Chang AY
Diabetologia; 1984 Aug; 27(2):225-34. PubMed ID: 6386585
[TBL] [Abstract][Full Text] [Related]
4. The relationship between hyperglycaemia and renal immune complex deposition in mice with inherited diabetes.
Meade CJ; Brandon DR; Smith W; Simmonds RG; Harris S; Sowter C
Clin Exp Immunol; 1981 Jan; 43(1):109-20. PubMed ID: 7018755
[TBL] [Abstract][Full Text] [Related]
5. Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse.
Bower G; Brown DM; Steffes MW; Vernier RL; Mauer SM
Lab Invest; 1980 Oct; 43(4):333-41. PubMed ID: 7003252
[TBL] [Abstract][Full Text] [Related]
6. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
Arakawa K; Ishihara T; Oku A; Nawano M; Ueta K; Kitamura K; Matsumoto M; Saito A
Br J Pharmacol; 2001 Jan; 132(2):578-86. PubMed ID: 11159708
[TBL] [Abstract][Full Text] [Related]
7. Effect of varied protein intake on the nephropathy of the diabetic mouse (C57BL/s J db/db).
Brouhard BH; Rajaraman S; LaGrone LF
Int J Pediatr Nephrol; 1987; 8(2):59-68. PubMed ID: 3308729
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice.
Chen S; Iglesias-de la Cruz MC; Jim B; Hong SW; Isono M; Ziyadeh FN
Biochem Biophys Res Commun; 2003 Jan; 300(1):16-22. PubMed ID: 12480514
[TBL] [Abstract][Full Text] [Related]
9. Ciglitazone prevents and reverses dexamethasone-induced hyperglycemia in female viable yellow mice.
Yen TT; Gill AM; Powell JG; Sampson BM
Int J Obes Relat Metab Disord; 1992 Nov; 16(11):923-33. PubMed ID: 1337348
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
McCarthy KJ; Routh RE; Shaw W; Walsh K; Welbourne TC; Johnson JH
Kidney Int; 2000 Dec; 58(6):2341-50. PubMed ID: 11115068
[TBL] [Abstract][Full Text] [Related]
11. Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
Sen U; Rodriguez WE; Tyagi N; Kumar M; Kundu S; Tyagi SC
Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1205-12. PubMed ID: 18780770
[TBL] [Abstract][Full Text] [Related]
12. Prevention of diabetic nephropathy by diet control in the db/db mouse.
Lee SM; Bressler R
Diabetes; 1981 Feb; 30(2):106-11. PubMed ID: 7009265
[TBL] [Abstract][Full Text] [Related]
13. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH
Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042
[TBL] [Abstract][Full Text] [Related]
14. Reno-protection of G004, a novel anti-diabetic sulfonylurea in db/db mice.
Tong X; Ma H; Amadi SW; Ma L; Wu G
Naunyn Schmiedebergs Arch Pharmacol; 2015 Aug; 388(8):831-41. PubMed ID: 25943026
[TBL] [Abstract][Full Text] [Related]
15. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Moriyama T; Oka K; Ueda H; Imai E
Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
[TBL] [Abstract][Full Text] [Related]
16. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
Wang LH; Liu JS; Ning WB; Yuan QJ; Zhang FF; Peng ZZ; Lu MM; Luo RN; Fu X; Hu GY; Wang ZH; Tao LJ
Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
[TBL] [Abstract][Full Text] [Related]
17. The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models.
Chang AY; Wyse BM
Prog Clin Biol Res; 1988; 265():177-92. PubMed ID: 3043443
[No Abstract] [Full Text] [Related]
18. Chrysin inhibits diabetic renal tubulointerstitial fibrosis through blocking epithelial to mesenchymal transition.
Kang MK; Park SH; Choi YJ; Shin D; Kang YH
J Mol Med (Berl); 2015 Jul; 93(7):759-72. PubMed ID: 26062793
[TBL] [Abstract][Full Text] [Related]
19. Potential hypoglycemic effect of an ethanol extract of Gynostemma pentaphyllum in C57BL/KsJ-db/db mice.
Yeo J; Kang YJ; Jeon SM; Jung UJ; Lee MK; Song H; Choi MS
J Med Food; 2008 Dec; 11(4):709-16. PubMed ID: 19053864
[TBL] [Abstract][Full Text] [Related]
20. Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? mice.
Chang AY; Gilchrist BJ; Wyse BM
Diabetologia; 1983 Dec; 25(6):514-20. PubMed ID: 6662280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
